Skip to main content

An unusually glycosylated form of acetylcholinesterase is a CSF biomarker for Alzheimer's disease

Buy Article:

The full text article is temporarily unavailable.

We apologise for the inconvenience. Please try again later.

The identification of a biochemical marker of Alzheimer's disease (AD) is a major research aim of many groups. Abnormal levels of tau and Aβ have been identified in the cerebrospinal fluid (CSF) of AD patients, although the sensitivity and specificity of the changes in these two biomarkers alone is not sufficient to be of diagnostic value. Recently, our group has identified an abnormality in the glycosylation of acetylcholinesterase (AChE). The increase in this glycoform of AChE is very specific for Alzheimer's disease and is not seen in many other neurological diseases including other dementias.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Alzheimer's disease; acetylcholinesterase; amyloid; cholinergic; diagnosis; glycosylation

Document Type: Original Article

Affiliations: Dept of Pathology, University of Melbourne, Parkville, Victoria 3052, Australia

Publication date: 2000-12-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more